| Literature DB >> 27313887 |
Tadesse Belayneh1, Afework Kassu2, Desalgne Tigabu3, Gashaw Asmare4, Sofanit Tilaye4, Eveline Klinkenberg5.
Abstract
Background. During tuberculosis treatment, patients may transfer to continue treatment at another health facility. To ensure adherence until treatment completion, keeping track of patients is paramount. This study aimed to investigate treatment outcomes of patients who transferred out from the University of Gondar Hospital. Methods. This was a retrospective cohort evaluation of patients registered from 2009 to 2013. Treatment outcomes were collected from the TB registers of receiving units using a standardized data capture format. Results. During the study period 3,707 patients initiated treatment and 47.5% (1,760) transferred out. The study evaluated the outcome of 26% (457/1,760) patients, of whom 403 (88%) arrived in the receiving units. Overall, 79% were successfully treated and 13.8% transferred out for a second time. For all transferred-out cases, treatment outcomes were not reported to the referring unit. Conclusion and Recommendation. About half of the patients were transferred out to complete treatment elsewhere. Although successful treatment outcome was obtained in 79% of patients, these results were not fed back to the referring unit. Implementing a clear mechanism to communicate the arrival of and treatment outcome for transfer-out patients and appropriate patient education on treatment unit selection before treatment and during transfer-out are recommended.Entities:
Year: 2016 PMID: 27313887 PMCID: PMC4904106 DOI: 10.1155/2016/1294876
Source DB: PubMed Journal: Tuberc Res Treat ISSN: 2090-150X
Characteristics of transferred-out PTB patients at the University of Gondar Hospital and those who arrived and did not arrive at selected receiving units, respectively, Ethiopia, 2009–2013.
| Characteristics | Transfer-out ( | Arriving ( | Nonarriving ( |
|---|---|---|---|
|
| |||
| Male | 271 (59.3) | 244 (90.0) | 27 (10.0) |
| Female | 186 (40.7) | 159 (85.5) | 27 (14.5) |
|
| |||
|
| |||
| ≤18 | 137 (30.0) | 111 (81.1) | 26 (18.9) |
| 19–34 | 183 (40.0) | 168 (91.8) | 15 (8.2) |
| 35–54 | 106 (23.2) | 98 (92.5) | 8 (7.5) |
| ≥55 | 31 (6.8) | 26 (83.9) | 5 (16.1) |
|
| |||
|
| |||
| Smear-positive | 108 (23.6) | 99 (91.7) | 9 (8.3) |
| Smear-negative | 349 (76.4) | 304 (87.1) | 45 (12.9) |
|
| |||
|
| |||
| New | 420 (91.9) | 368 (87.6) | 52 (12.4) |
| Relapse | 27 (5.9) | 26 (96.3) | 1 (3.7) |
| Return after default | 4 (0.9) | 4 (100.0) | 0 (0.0) |
| Failure | 6 (1.3) | 5 (83.3) | 1 (16.7) |
|
| |||
|
| |||
| Negative | 284 (62.1) | 247 (86.9) | 37 (13.1) |
| Positive | 173 (37.9) | 156 (90.2) | 17 (9.8) |
|
| |||
|
| |||
| <4 weeks | 85 (18.6) | 79 (92.9) | 6 (7.1) |
| 4–12 weeks | 365 (79.9) | 317 (86.8) | 48 (13.2) |
| >12 weeks | 7 (1.5) | 7 (100.0) | 0 (0.0) |
Treatment outcomes of transferred PTB patients who arrived at their receiving facility in northwest Ethiopia, 2009–2013 (N = 403).
| Characteristics | Treatment outcomes | |||||
|---|---|---|---|---|---|---|
| Cured | Treatment completed | Default | Failure | Death | Transfer-out | |
|
| ||||||
| ≤18 | 17 (22.4) | 72 (29.8) | 0 (0) | 0 (0) | 6 (30.0) | 16 (28.6) |
| 19–34 | 29 (38.2) | 96 (39.7) | 6 (85.7) | 2 (100.0) | 8 (40.0) | 27 (48.2) |
| 35–54 | 24 (31.6) | 57 (23.6) | 1 (14.3) | 0 (0) | 4 (20.0) | 12 (21.4) |
| ≥55 | 6 (7.9) | 17 (7.0) | 0 (0) | 0 (0) | 2 (10.0) | 1 (1.8) |
|
| ||||||
|
| ||||||
| Male (=244) | 43 (17.6) | 145 (59.4) | 4 (1.6) | 1 (0.4) | 14 (5.7) | 37 (15.2) |
| Female (=159) | 33 (20.7) | 97 (61.0) | 3 (1.9) | 1 (0.6) | 6 (3.8) | 19 (11.9) |
|
| ||||||
|
| ||||||
| Smear-positive | 42 (42.4) | 35 (35.3) | 2 (2.0) | 0 (0) | 4 (4.0) | 16 (16.2) |
| Smear-negative | 34 (11.2) | 207 (60.1) | 5 (1.6) | 2 (0.6) | 16 (5.3) | 40 (13.1) |
|
| ||||||
|
| ||||||
| New | 66 (17.9) | 223 (60.6) | 6 (1.6) | 2 (0.5) | 19 (5.2) | 52 (14.1) |
| Relapse | 8 (30.8) | 14 (53.8) | 0 (0) | 0 (0) | 1 (3.8) | 3 (11.5) |
| Default | 1 (25.0) | 2 (50.0) | 0 (0) | 0 (0) | 0 (0) | 1 (25.0) |
| Failure | 1 (20.0) | 3 (60.0) | 1 (20.0) | 0 (0) | 0 (0) | 0 (0) |
|
| ||||||
|
| ||||||
| Positive (=155) | 23 (14.8) | 96 (61.9) | 1 (0.6) | 1 (0.6) | 11 (7.1) | 23 (14.8) |
| Negative (=248) | 53 (21.4) | 146 (58.8) | 6 (2.4) | 1 (0.4) | 9 (3.6) | 33 (13.3) |
|
| ||||||
|
| ||||||
| Same to 2nd day | 31 (19.3) | 91 (56.8) | 3 (1.8) | 1 (0.6) | 13 (8.1) | 21 (13.1) |
| 3rd day | 35 (19.2) | 110 (60.4) | 4 (2.2) | 1 (0.5) | 5 (2.7) | 27 (14.8) |
| ≥4th day | 5 (23.8) | 14 (66.6) | 0 (0) | 0 (0) | 1 (4.8) | 1 (4.8) |
|
| ||||||
|
| ||||||
| Intensive | 59 (21.1) | 163 (58.2) | 5 (1.9) | 1 (0.3) | 14 (5.0) | 38 (13.5) |
| Continuation | 17 (13.8) | 79 (64.2) | 2 (1.6) | 1 (0.8) | 6 (4.8) | 18 (14.6) |
|
| ||||||
|
|
|
|
|
|
|
|